Nurse Practitioner in Gentry, AR Accepting Medicare
4 Nurse Practitioner nurses found. Showing 1 - 4
 Meghan Williams, Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 644 Red Oak St, Gentry, AR 72734 Phone: 479-856-5750 Fax: 479-856-5750 |
Kindal Dawn Reynolds, APRN Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 643 E 3rd St, Gentry, AR 72734 Phone: 479-736-2213 Fax: 479-373-6095 |
April Lee Leavengood, CNP Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 22946 W Highway 12, Gentry, AR 72734 Phone: 479-238-3303 |
Catherine Elaine Casey, Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 643 E 3rd St, Gentry, AR 72734 Phone: 479-736-2213 Fax: 479-736-2105 |
News Archive
Genetic risk score may help detect Alzheimer's disease risk in healthy young adults
New research shows that a genetic risk score may detect those at higher risk for Alzheimer's disease long before symptoms appear—even possibly in healthy young adults, according to a study published in the July 6, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology.
PTCL trial data on belinostat to be presented at 2010 ASCO Annual Meeting
Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in hematology and oncology, today announced that clinical data on belinostat will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology, to be held June 4-8, 2010 at the McCormick Place Convention Center in Chicago, Illinois, as part of the ASCO proceedings.
People who eat bushmeat may be at risk of contracting life-threatening diseases
People who eat wildebeests, wart hogs and other wild African animals may be at risk for contracting potentially life-threatening diseases, according to an international team of researchers.
Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic
Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.
› Verified 3 days ago